Tamoxifen and raloxifene, and the aromatase inhibitors exemestane and anastrozole, all significantly reduce the incidence of primarily ER-positive and (PR)-positive breast cancers, but again no reduction in breast cancer deaths has been observed. This evidence concerns the gene CYP19A1 and breast cancer.